Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

Stopped Based on initially defined safety rules not continued with expansion phase of study (too much toxicity with neo-adjuvant immunotherapy)

Conditions

• Stage III NSCLC

Interventions

• DRUG: Durvalumab
• DRUG: Tremelimumab
• DRUG: Pemetrexed
• DRUG: Cisplatin
• RADIATION: chemo radiotherapy
• PROCEDURE: Resection

Sponsor

The Netherlands Cancer Institute

Collaborators

• [object Object]